Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent B-cell NHL”

128 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 128 results

Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Testing effectiveness (Phase 2)WithdrawnNCT00003605
What this trial is testing

Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Study completedNCT01206777
What this trial is testing

Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

Who this might be right for
Indolent or Intermediate Grade B-cell Malignancy
Ohio State University Comprehensive Cancer Center 52
Testing effectiveness (Phase 2)Study completedNCT03583424
What this trial is testing

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+9 more
Ohio State University Comprehensive Cancer Center 19
Testing effectiveness (Phase 2)Study completedNCT00720876
What this trial is testing

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
City of Hope Medical Center 30
Not applicableUnknownNCT05803395
What this trial is testing

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Who this might be right for
Chronic Lymphocytic LeukemiaIndolent B-Cell Non-Hodgkin LymphomaCOVID-19
Gruppo Italiano Malattie EMatologiche dell'Adulto 954
Testing effectiveness (Phase 2)Study completedNCT02362035
What this trial is testing

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Who this might be right for
Follicular Lymphoma (FL)CLLSmall Lymphocytic Lymphoma (SLL)+10 more
Acerta Pharma BV 161
Testing effectiveness (Phase 2)Study completedNCT04298879
What this trial is testing

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Who this might be right for
Indolent Non-hodgkin Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 81
Early research (Phase 1)Study completedNCT01088048
What this trial is testing

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin's LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma
Gilead Sciences 241
Testing effectiveness (Phase 2)Active Not RecruitingNCT03198026
What this trial is testing

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Who this might be right for
Non-Hodgkin's LymphomaAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage II Follicular Lymphoma+16 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 30
Large-scale testing (Phase 3)Ended earlyNCT01289223
What this trial is testing

A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.

Who this might be right for
Indolent B-cell NHL
Mundipharma Research Limited 88
Testing effectiveness (Phase 2)Active Not RecruitingNCT05202782
What this trial is testing

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+16 more
Northwestern University
Testing effectiveness (Phase 2)Active Not RecruitingNCT03625037
What this trial is testing

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Who this might be right for
DLBCLHigh-grade B-cell Lymphoma (HGBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)+6 more
Genmab 666
Testing effectiveness (Phase 2)Active Not RecruitingNCT04245839
What this trial is testing

Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 276
Large-scale testing (Phase 3)Active Not RecruitingNCT03984448
What this trial is testing

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Who this might be right for
Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedDouble-Expressor Lymphoma+5 more
National Cancer Institute (NCI) 363
Early research (Phase 1)Active Not RecruitingNCT05878184
What this trial is testing

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Who this might be right for
Non Hodgkin LymphomaChronic Lymphocytic Leukemia
Sana Biotechnology 16
Large-scale testing (Phase 3)Ended earlyNCT01732913
What this trial is testing

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Who this might be right for
Indolent Non-Hodgkin's Lymphomas
Gilead Sciences 295
Testing effectiveness (Phase 2)Study completedNCT00087425
What this trial is testing

Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
National Institute on Aging (NIA) 48
Testing effectiveness (Phase 2)UnknownNCT00927797
What this trial is testing

Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)

Who this might be right for
Immunocytoma/Morbus WaldenströmB-Cell Non-Hodgkin's LymphomaB-Cell Chronic Lymphocytic Leukemia
Heidelberg University 185
Testing effectiveness (Phase 2)Study completedNCT03035331
What this trial is testing

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

Who this might be right for
Aggressive Non-Hodgkin LymphomaIndolent Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+7 more
Mayo Clinic 11
Load More Results
24